INTRODUCTION
Prion diseases (PrDs) are a variety of fatal neurodegenerative diseases including Gerstmann -Sträussler -Scheinker (GSS) syndrome, familial fatal insomnia (FFI), Creutzfeldt-Jakob disease (CJD) and kuru in humans, scrapie in sheep and goats, bovine spongiform encephalopathy (BSE) in cattle and chronic wasting disease in mule deer and elk (1, 2) . Key pathological features of PrD are progressive degeneration of neurons without classical inflammation, formation of proteinase-K (PK)-resistant pathological prion protein (PrP Sc ) deposits in neurons and spongiform encephalopathy (2) . Although the majority of PrD cases in humans are classified as sporadic forms of CJD, molecular cloning of the prion protein gene (PRNP) linked to inherited PrD (IPrD) has provided tremendous contributions to understanding pathogenesis of PrD. IPrDs caused by mutations in PRNP have been annotated in GSS, FFI and familial CJD (3) . More than 30 different pathogenic mutations in PRNP can be divided into three molecular categories: a point mutation leading to the substitution of an amino acid or an early stop codon or the insertion of extra octapeptide repeats (4) .
At least 10 different pathogenic mutations in PRNP have been shown to induce clinical symptoms and pathological features belonging to GSS syndrome which is characterized by prominent progressive cerebellar ataxia with dementia and multicentric amyloid plaques in the cerebellum and cerebral cortex (4 -8) . The most common and most thoroughly investigated mutation is a substitution of leucine for proline at residue 102 (P102L) of human PrP that converts PK-susceptible human PrP (HuPrP C ) to PK-resistant PrP (HuPrP Sc ) (7,9 -13) . Studies in the largest kindred with P102L GSS syndrome showed that phenotypic heterogeneity was present and preclinical silence periods may be influenced by an SNP at codon 129 of PrP (13) . Phenotypic heterogeneities reported for GSS syndrome and other PrD patients suggested that pathogenesis is the result of a complex series of steps or interventions of pathways and that these events might be influenced by unknown environmental and/or genetic risk factors.
Recent studies aimed at identifying pathways involved with onset and progression of PrD suggested that programmed cell death (PCD) and synaptic dysfunction may contribute to clinical manifestation of PrDs (14) (15) (16) . Apoptotic cell death was consistently observed in brains with PrDs, especially retina and cerebellum in which spongiform degeneration was minimal or absent (17) . Autophagic vacuoles in different sizes and stages of formation in PrD brains suggested that expansion of autophagic vacuoles may contribute to spongiform encephalopathy (16) . Pre-synaptic bouton degeneration and dendritic atrophy were observed from PrD brains at terminal stages (18) (19) (20) (21) . More detailed studies using mouse PrD models showed that synaptic dysfunction may represent pre-symptomatic alterations in brains (22) (23) (24) (25) (26) . Compared with recordings from pyramidal cells of age-matched control mice, attenuated Shaffer collateral-evoked EPSP, depolarized resting membrane potentials and an increased membrane resistance were recorded from pyramidal cells from scrapie-infected mice (27) . Those studies indicate that pre-symptomatic alteration of synaptic structures and functions may be one of the key steps responsible for the manifestation of clinical symptoms.
To understand molecular and cellular pathophysiologies underlying GSS syndrome, transgenic (TG) mouse models were generated by expressing mouse PrP having leucine substitution at residue 101 (P101L), homologous to P102L mutation in human PrP. The TG mice over-expressing mouse (Mo) PrP P101L recapitulated key pathological features of GSS syndrome in humans. For example, MoPrP P101L TG mice showed spontaneous spongiform degeneration and gliosis in the brains with spontaneously developed neurological dysfunction in old age (28, 29) . However, knock-in TG mice expressing MoPrP P101L under the control of endogenous promoter do not manifest pathological phenotypes and live a normal life span (30, 31) . Thus, the exact mechanisms underlying onset and progression of P102L GSS syndrome are still unknown.
Drosophila has been extensively utilized as a genetic model for elucidating unknown molecular and cellular etiologies underlying human diseases. Evolutionarily conserved molecular components at synapses and basic neuronal signaling pathways between Drosophila and humans allow us to investigate molecular and cellular patho-physiologies underlying various neurological disorders in humans (32, 33) . In this study, we have generated Drosophila models of GSS syndrome by transgenically introducing MoPrP P101L . We found that MoPrP P101L flies phenocopied several key behavioral symptoms and pathological hallmarks reported from human and TG mice with GSS syndrome. Those symptoms were not suppressed by the expression of P35, a viral apoptotic inhibitor. In addition, MoPrP P101L induced altered synaptic architectures in larval neuromuscular junctions and progressive reduction of an active zone marker, Bruchpilot (Brp), and a synaptic scaffolding protein, Discs large (DLG), in adult brains. Since similar alteration of an active zone marker was confirmed in scrapie-infected mouse brains, the alteration of active zones at synapses may be an important molecular pathogenic mechanism underlying various PrDs.
RESULTS

Development of a Drosophila model of GSS syndrome
To develop a model of GSS syndrome in Drosophila, we utilized the Gal4/UAS bi-partisan system to induce the expression of mouse and MoPrP P101L in transgenic Drosophila. No band was observed in larvae carrying the driver (Tub-Gal4/+) alone, even though a comparable amount of a-tubulin was detected by MAb-a-tubulin (Fig. 1A ). There were no significant differences in the amount of expressed MoPrPs among tested transgenic lines when they were normalized with loading controls (Fig. 1B) P101L . Flies staying at the bottom of vials after agitation of vials on a vortex mixer for 10 s followed by 20 s without agitation (Supplementary Material, Movie S1) were considered to have behavioral defects. More than 70% of 30-day-old MoPrP 3F4 flies were able to climb and stay at the top or wall of the vials. However, MoPrP P101L flies showed severe climbing defects even at day 10. Less than 20% of flies were able to climb the vials. Those defects were even more severe at 20 or 30 days of age (Fig. 1C) and rabbit anti-Drosophila synaptotagmin (DSypt) antibodies ( Fig. 2A-C) . The larval central nervous system (CNS) and ventral nervous system (VNS) of control (Tub-Gal4/+) flies did not show any PrP immunoreactivity, even though synaptic vesicle pools in the CNS and the VNS were clearly detected by DSypt antibodies ( Fig. 2A) . In contrast, in Drosophila transgenic for MoPrP 3F4 or MoPrP P101L , PrP immunoreactivity was detected in the CNS and the VNS. In addition, stronger PrP immunoreactivity was localized at the synaptic regions of mushroom bodies in the CNS and the neurophil regions of the VNS which were revealed by DSypt immunoreactivity (Fig. 2B and C) .
To test whether two different MoPrPs were targeted to the synaptic terminals, Type 1 glutamatergic synaptic boutons in larval neuromusclar junctions (NMJs) expressing either MoPrP 3F4 or MoPrP P101L were examined by performing double-labeling immunocytochemistry utilizing MAb-PrP 3F4 together with one of several antibodies specific to synaptic molecular components. When MoPrPs were expressed at the pre-and the post-synaptic terminals, strong PrP immunoreactivity was observed from the pre-and post-synaptic terminals of Type 1 glutamatergic synaptic boutons (Fig. 2D -I) . Synaptic vesicles at the pre-synaptic terminals were partially colocalized with PrP immunoreactivity (Fig. 2D and G) . Immunoreactivity of DLG that is present mainly at the post-synaptic terminal subsynaptic reticulum structures (36) was overlapped with PrP immunoreactivity (Fig. 2E and H) . The post-synaptic density structures revealed by rabbit antiDrosophila p21-activated kinase antibodies were encompassed by PrP immunoreactivity (Fig. 2F and I ). These double-labeling immunocytochemistry results suggested that expressed MoPrPs were targeted or moved to the synaptic terminals of Type 1 glutamatergic larval NMJs.
By utilizing the neuronal-specific C155-Gal4 driver and the muscular-specific C57-Gal4 drivers, we further examined whether the motor neuron-specific or the muscular-specific expression of MoPrPs are enough to target or move MoPrPs to the synaptic terminals. When MoPrPs were expressed at the motor neurons, PrP immunoreactivity was completely enclosed by the immunoreactivity of a neuronal membranespecific marker, goat anti-Horse Radish Peroxidase (HRP) antibodies ( Fig. 2J and K) . When MoPrPs were expressed at the muscles, PrP immunoreactivity surrounded HRP immunoreactivity ( Fig. 2L and M) and mostly overlapped with DLG immunoreactivity (Fig. 2N and O) . These results suggested that the motor neuron-specific or the muscular-specific expression of MoPrPs were enough to target or move MoPrPs to the pre-or post-synaptic terminals of Type 1 glutamatergic NMJs, respectively.
Expressed MoPrP
P101L accumulated in Drosophila adult brains, but was resistant to PK digestion and enzymatic deglycosylation
To determine whether the amount of MoPrPs in the adult brains in Drosophila was progressively increased or not, we employed UAS-MoPrP 3F4 (123) flies and UAS-MoPrP P101L (223) flies expressing similar amounts of MoPrP at the third instar larvae to further studies ( Fig. 3A and B) . Protein extracts from 1-, 10-, 20-and 30-day-old adult heads were analyzed using MAb-PrP 3F10 and MAb-a-tubulin for quantifying the amount of MoPrPs in brains. The amount of MoPrPs in brains expressing MoPrP 3F4 and MoPrP P101L gradually increased as flies aged (Fig. 3A ). There were no significant differences in the amount of MoPrPs between MoPrP 3F4 and MoPrP P101L flies when they emerged (Fig. 3A) . However, the amount of MoPrP P101L in brains of 10-, 20-and 30-day-old MoPrP P101L flies was significantly more than that of MoPrP 3F4 in age-matched MoPrP 3F4 flies ( Fig. 3A and B). To verify that expression-level differences of Prnp mRNA in MoPrP 3F4 (123) flies and MoPrP P101L (223) flies did not contribute to different amounts of MoPrPs in aged adult heads, we extracted total RNA from 12-h-old embryos, first instar larvae (24 h after egg laying), second instar larvae (48 h after egg laying), early third instar larvae (72 h after egg laying), late third instar larvae (96 h after egg laying), 1-day-old adult flies and 10-day-old adult flies and performed semi-quantitative reverse transcriptasepolymerase chain reaction (RT-PCR) experiments (Fig. 3C) (Fig. 4A ). In addition, the treatment of PNGase F induced the disappearance of a 32 kDa band indicated by an arrowhead in MoPrP 3F4 and MoPrP 3F10 (Fig. 4B ). Even though 20 kDa bands in MoPrP P101L were reduced when PK and PNGase F were used simultaneously, one of two 20 kDa bands completely disappeared in MoPrP 3F4 (Fig. 4B ). Similar biochemical features of glycosylated HuPrPs (37, 38) and mouse TG models (39, 40) have been reported. Thus, biochemical evidence suggests that MoPrPs in Drosophila have similar biochemical features as those expressed in the TG mouse brains with GSS syndrome and human cells over-expressing HuPrP P102L .
Expression of MoPrP P101L in cholinergic neurons was sufficient to induce climbing defects and early death in Drosophila
To identify which circuits in the nervous systems or tissues in Drosophila are responsible for age-dependent progressive motor defects in MoPrP P101L flies, we utilized several previously characterized Gal4 driver flies. We employed Tub-Gal4 and Actin-5C (Act-5C)-Gal4 driver flies for ubiquitous expression of MoPrP 3F4 or MoPrP P101L because PrP and PRNP mRNA are present in neuronal and non-neuronal tissues in humans and mammals (41) . We also employed C155-Gal4 driver flies for pan-neuronal expression, Choline acetyltransferase (Cha)-Gal4 driver flies for cholinergic , total mRNAs were extracted from embryos (12 h after egg laying), first instar larvae (24 h after egg laying), second instar larvae (48 h after egg laying), early third instar larvae (72 h after egg laying), late third instar (96 h after egg laying), 1-day-old adult flies and 10-day-old adult flies and then processed for semi-quantitative RT-PCR (Q-RT-PCR). (C) RT-PCR products of Prnp mRNAs from 15, 30, 45 cycles were compared. Similar Prnp mRNA levels were detected during development. Actin-5C was used as loading control. Asterisk indicates significant differences at P , 0.01. neuronal expression, 3,4-dihydroxyphenylalanine-L-decarboxylase (Ddc)-Gal4 driver flies for mainly dopaminergic neuronal expression, Gliotactin (Glio)-Gal4 drivers flies for expressing in subsets of glial cells, C57-Gal4 driver flies for muscular-specific expression and 201Y-Gal4 driver flies for mushroom body expression to examine important tissues or circuits for manifesting severe behavioral symptoms. Genetic background carrying only Gal4-driver (Gal4/+) or transgenes (UAS-MoPrP/+) was used as a control for this study. We examined two UAS-MoPrP controls, UAS-MoPrP 3F4 /+ and UAS-MoPrP P101L /+, neither of which showed any significant difference in climbing ability and survival rates (Supplementary Material, Fig. S1 ).
The striking differences in behavior were observed when MoPrP P101L was expressed in all tissues or cholinergic neurons (Fig. 5) . When Tub-Gal4 and Act-5C-Gal4 were used for ubiquitous expression of MoPrP 3F4 or MoPrP P101L , MoPrP P101L flies showed severe defects in climbing ability even at day 5. After 20 days of age, more than 90% of MoPrP P101L flies were not able to climb (Supplementary Material, Movie S1, Mutant). In contrast, more than 50% of MoPrP 3F4 flies and controls were able to climb the vials (Supplementary Material, Movie S1, Wild). Interestingly, when Cha-Gal4 driver was employed, more than 90% of flies failed to pass the climbing test at 20 days of age. A similar, but delayed, climbing defect was observed when panneuronal C155-Gal4 driver was used. After 55 days of age, more than 90% of flies were incapable of climbing the vials. Flies expressing MoPrP P101L in mainly dopaminergic neurons (Ddc-Gal4), mushroom body (201Y-Gal4), subsets of glial cells (Glio-Gal4) and muscles (C57-Gal4) did not show any obvious climbing disability (Supplementary Material, Fig. S2 ).
Expression of MoPrP P101L in all tissues by Tub-Gal4 or Act-5C-Gal4 significantly induced the early death of flies ( Fig. 6A and B) . Even though half of the controls and half of the MoPrP 3F4 flies lived until 70 days of age, more than 50% of flies expressing MoPrP P101L generated by Tub-Gal4 or Act-5C-Gal4 were dead at 25 and 30 days of age, respectively ( Fig. 6A and B) . When MoPrP P101L was expressed in all neurons (Fig. 6C) (Fig. 7A, C and E) . In contrast, strong PrP immunoreactivity, mainly presenting as deposits, was observed in the midline brain section of MoPrP P101L flies (Fig. 7B, D and F) . We further analyzed the degeneration of neurons by performing hematoxylin and eosin (H&E) staining. The adult brains of MoPrP 3F4 flies did not show any obvious vacuoles (Fig. 7A, G and I) . Various sizes of vacuoles, indicated by black arrows from several parts, were observed in the brains of MoPrP P101L flies (Fig. 7B, H and J) . We counted the number of vacuoles bigger than 5 mm in diameter from 20-day-old flies expressing MoPrP 3F4 or MoPrP P101L . MoPrP P101L flies had a 5-fold increase in the number of vacuoles compared with MoPrP 3F4 flies (Table 1) . Vacuoles were more often observed at the superior medial protocerebrum (Fig. 7H) , the lobula and the lobula plate in adult heads (Fig. 7J) . These results suggested that MoPrP P101L in adult heads formed deposits and induced vacuoles.
Expression of MoPrP
P101L induced altered synaptic architecture of Type I glutamatergic larval NMJs
In this study, we have shown that MoPrPs were localized at the synaptic terminals in Type 1 glutamatergic larval NMJs (Fig. 2) . To determine whether MoPrP P101L expression resulted in any structural defects at synapses, we further examined Type 1 glutamatergic synapses in larval NMJs by staining with a neuronal membrane-specific marker, anti-HRP antibody. Type 1 glutamatergic NMJs expressing MoPrP P101L in all tissues or neurons had more small-sized satellite boutons (Fig. 8 , white arrows) than those of controls or MoPrP 3F4 NMJs ( Fig. 8J and K) . However, the muscular-specific expression of MoPrP P101L did not increase the number of satellite boutons (Fig. 8L) . These results were consistent with behavioral analysis results and suggested that the neuronal (Fig. 9A -D) . Relative Brp-specific intensities observed from synaptic boutons and brains of MoPrP P101L larvae were 50 and 80%, respectively, of intensities seen in MoPrP 3F4 larvae ( Fig. 9E and F) . We did not find any significant alteration in the localization patterns or amounts of other synaptic molecular components in the brains and the synaptic boutons of MoPrP P101L larvae (data not shown).
We further examined by western blot analysis whether Brp in adult heads of MoPrP P101L flies was also altered. Two Brp-specific bands around 150 kDa were significantly reduced in 30-day-old MoPrP P101L flies compared with those of age-matched MoPrP 3F4 flies ( Fig. 9G and H) . In addition, the amount of DLG in adult heads was also significantly decreased in 30-day-old flies ( Fig. 9G and I) . These results suggested that the amounts of Brp and DLG in the adult head are continuously decreasing as flies age and that significantly reduced amounts of Brp and DLG in the synapses of MoPrP P101L brains may be the basis of severe phenotypic abnormalities.
Reduced ELKS, a component of cytoskeletal matrix assembled at active zones and Synaptotagmin I in scrapie-infected mice
To examine whether the amount of ELKS, a component of cytoskeletal matrix at active zone (CAZ) in the hippocampi of scrapie-infected mouse brains, was altered, ELKS in scrapie-infected mice hippocampi was compared with that in the control mouse hippocampi. There was a 20% reduction in the level of ELKS in the hippocampi of scrapie-infected mice compared to control hippocampi (Supplementary Material, Fig. S4A ). In addition, the amount of Sypt I in scrapie hippocampi was reduced to 50% of the level in , the ratio between the number of satellite boutons and the total number of synaptic boutons was significantly increased compared with genetic background flies or flies expressing MoPrP 3F4 when Tub-Gal4 drivers (J) and pan-neuronal C155-Gal4 driver (K), but not the muscular-specific C57-Gal4 driver (L), were used. Statistical analysis was performed by one-way ANOVA (Duncan's method, SAS program). Different letters such as 'a' or 'b' were used to label statistically different groups (P , 0.01).
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Human Molecular Genetics, 2010, Vol. 19, No. 22 Fig. S4A ). These results suggested that scrapie-infected mouse brains also showed a reduced amount of CAZ and synaptic vesicle pools at the synaptic terminals.
Expression of P35, viral anti-apoptotic proteins did not suppress abnormal behavior
To test whether PCD contributed to severe defects in climbing ability and early death of MoPrP P101L , P35, a viral Caspase 3 inhibitor, was expressed together with MoPrP P101L in cholinergic neurons (Figs 5D and 6D ). The numbers of climbing flies between MoPrP P101L alone or together with P35 were similar (Fig. 5D) . These results suggested that the climbing disability observed from MoPrP P101L flies was not due to activation of Caspase 3-dependent PCD pathways.
The concomitant expression of P35 and MoPrP P101L in flies significantly induced early death of flies compared with controls, MoPrP 3F4 flies, P35 flies and MoPrP P101L flies (Fig. 6D) . These synergistic effects of P35 and MoPrP P101L in the early death of flies suggested that the death of MoPrP P101L flies was regulated by one or more unknown pathways that are independent upon Caspase 3.
DISCUSSION
A Drosophila model of GSS syndrome recapitulates key pathological hallmarks of GSS syndrome
The major goal of the present study was to develop a Drosophila model of GSS syndrome to gain insight into the mechanisms by which GSS mutant PrP induces clinical symptoms of GSS syndrome. Recent studies utilizing TG animal models have shown that highly over-expressed wild-type PrPs have given rise to phenotypic abnormalities that were similar to those of PrD models. For example, the highly over-expressed wild-type hamster PrP in flies resulted in degenerative phenotypes in a dose-dependent manner (42) . In addition, TG mice over-expressing MoPrP 3F4 10-fold, but not 5-fold, developed spontaneous neurodegenerative symptoms such as tremor, paralysis and early death (43) . Even though Gavin et al. (44) have shown that the expression of MoPrP P101L in flies induced accelerated accumulation of MoPrPs and spongiform degeneration in brains, the expressed amount of MoPrP P101L was .20-fold more than MoPrP 3F4 . Thus, their results are not enough to verify that the phenotypic abnormalities observed from MoPrP P101L are not due to differences in the amount of expressed PrPs. Therefore, to verify that any pathological abnormalities observed from flies expressing MoPrP P101L were not due to the differences in the amounts of expressed MoPrPs, we generated and examined the amount of expressed MoPrPs to select transgenic flies with similar amount of PrPs. Six independent transgenic flies did not show significant differences in the amount of expressed MoPrPs in western blot analysis (Fig. 1) without discrimination (Fig. 4) (45) . In addition, two lines extensively used in this study did not show any difference in the amount of expressed Prnp mRNAs throughout development (Fig. 3) . Thus, our most significant finding in this study is that the expression of MoPrP P101L , but not MoPrP 3F4 , either in all tissues or in the nervous systems of Drosophila, results in severe defects in climbing behavior and early death (Figs 5 and 6 ). . Nevertheless, the survival rates of all examined MoPrP 3F4 flies were not significantly different from those of controls ( Fig. 6 and Supplementary Material,  Fig. S3 ). In addition, MoPrP 3F4 flies do not have vacuoles, which were observed in the adult brains of MoPrP P101L flies ( Fig. 7 and Table 1 ).
Different from TG mouse and fly models over-expressing PrP P101L , knock-in TG mice expressing wild-type levels of MoPrP P101L under control of endogenous Prnp promoter do not exhibit spontaneous neurodegenerative symptoms (30, 31) . Instead, the incubation periods of those knock-in mice after inoculated with several scrapie strains were significantly altered (30, 31) . One possible explanation for this phenomenon is that knock-in TG mice may not live longer enough to develop spontaneous neurological symptoms since reported onset ages of GSS syndrome in humans are over 40 years (30, 31) . Another possibility is that more MoPrP P101L are required for manifesting spontaneous symptoms in knock-in mice models for GSS syndrome. Taken together, the amount of expressed normal or mutant PrPs in animals may be a critical factor for generating more appropriate animal models for GSS syndrome.
Similar to what has been observed in TG mouse models (28) and human cells over-expressing HuPrP P102L (38) , we found that MoPrPs in Drosophila are differentially glycosylated (Figs 1, 3 and 4) and localized at the synapses (Fig. 2) . In addition, MoPrP P101L showed increased resistance to PK digestion and deglycosylation compared with those of MoPrP 3F4 (Fig. 4) . In addition, significantly more MoPrP P101L accumulated in adult brains than did MoPrP 3F4 , even though the amount of the two MoPrPs in adult heads is progressively increasing (Fig. 3) . Furthermore, MoPrP P101L in adult brains is mainly present as deposits (Fig. 7) , which are reminiscent of multicentric amyloid plaques in human or TG mouse brains with GSS syndrome (29, 46) . Taken together, the expression of MoPrP P101L in flies is enough to recapitulate several key behavioral, biochemical and pathological hallmarks observed in human or TG mouse models with GSS syndrome.
Involvement of cholinergic neural circuits in Drosophila GSS syndrome
Another interesting finding in this study is the demonstration of the involvement of the cholinergic neural circuit in the induction of GSS syndrome in flies. Similar to findings in other neurodegenerative disorders in humans, certain types of neurons or parts of brains manifest pathological defects in PrDs, even though causative PrPs are expressed in tissues and cells other than brain neurons (47) (48) (49) . For example, MoPrP P101L TG mouse brains with phenotypic abnormalities showed severe vacuolation in the globus pallidus, cerebellum, substantia niagra, neocortex and caudate (29) . Even though it is still not clear whether cholinergic neurons in human brains with GSS syndrome are affected or not, a recent study in sporadic and variant CJD cases showed that dopaminergic neurons and striatal outflow neurons, but not cholinergic neurons, in the nigrostriatal pathway are significantly damaged (50) . How can we reconcile those differences between this report and our finding? One possibility is that the basic locomotor control neural circuits between Drosophila and mammals may be different, because they diverged at very early stages of animal evolution. Since many neurodegenerative disorders in humans, such as poly-glutamine repeat diseases (51), Parkinson's disease (52,53), Alzheimer's disease (54, 55) , early-onset torsion dystonia (56), amyotrophic lateral sclerosis (57) etc., have been successfully modeled using Drosophila, we do not support this possibility. Rather, the unique pathogenic feature of GSS syndrome may give some clue to reconcile this difference. The major components of aggregated and accumulated fibrillar amyloid deposits in the brains with GSS syndrome is a 7 kDa PrP fragment, spanning from residues 81-82 to 144-153 of PrP (58) which polymerizes into protease-resistant fibrils and triggers the cell death of murine cortical neurons (59) . A recent report has shown that acetylcholinesterase (AChE) promotes the fibrillization of pathogenic 7 kDa PrP fragments with GSS mutation in vitro in a dose-dependent manner (60) . Thus, it may be that AChE plays a pivotal role in the pathogenesis of the Drosophila model of GSS syndrome by triggering the fibrillization of MoPrP P101L , even though any alteration of AChE or cholinergic neurons in brains with GSS syndrome in humans has not as yet been reported. Thus, the second possibility is that MoPrP P101L expressed in cholinergic neurons in flies may interact with endogenous AChE at the synaptic clefts to become toxic pathogenic PrP deposits, resulting in phenotypic abnormalities. Therefore, it will be intriguing to examine any genetic interaction between MoPrP P101L flies and available Drosophila AChE (Ace) mutant animals to verify the contribution of Ace in MoPrP P101L -induced pathogenesis.
Altered synaptic and molecular architecture of Type 1 glutamatergic synaptic boutons in larval NMJs of MoPrP P101L flies
Synaptic dysfunctions clarified by the selective loss of presynaptic elements, degeneration of synapses and altered neuronal activities are observed in human and mouse brains with PrDs (24, 26, 61) . In this study, we also found several synapse-associated defects in MoPrP P101L larvae and adults; first, the small-sized satellite boutons in Type 1 glutamatergic larval NMJs were significantly increased when MoPrP P101L is present at the pre-synaptic terminals or the pre-and postsynaptic terminals (Fig. 8) . Expression of MoPrP P101L only at the post-synaptic terminal muscles did not induce any structural changes, suggesting that MoPrP P101L at the pre-synaptic terminal is necessary for inducing structural changes. Even though the alteration of synaptic morphology in the brains of
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the humans and TG mice with GSS syndrome are not well characterized, a growing body of evidence from other PrD models suggests that the progressive alteration of sizes and numbers of synapses may contribute to development and pathological changes in the PrD brains (62) . Second, Brp immunoreactivity is decreased at the synapses in the brains and Type 1 glutamatergic NMJs in MoPrP P101L larvae (Fig. 9) . In addition, MoPrP P101L flies showed a progressive reduction of expressed Brp in adult brains (Fig. 9) . Recent studies on loss of function in Brp-mutant flies have shown that Brp is localized at the active zones required for excitatory synaptic transmission and associated with locomotor controls in adult flies (63, 64) . We also found reduced DLG, which is responsible for orchestrating synaptic architecture by regulating localization of ion channels, neuronal cell adhesion molecules and receptors (65) in the adult heads (Fig. 9) . Thus, our results on changes at the molecular level help explain why MoPrP P101L flies manifested a progressive loss in climbing ability. We also showed that those synaptic component defects may not be restricted in MoPrP 
Inhibition of Caspase 3-dependent apoptotic neuronal cell death pathway did not suppress the onset of GSS symptoms in flies
Even though the premature, primary death of neurons underlies the clinical symptoms of PrDs, the cellular pathways leading to this neuronal cell death are not completely understood at this time (16) . PCD has been proposed to be involved with neuronal loss and vacuole formations in brains with PrDs (16, (66) (67) (68) (69) (70) (71) (72) . Even though DNA fragmentation and over-expressed Bax has been reported in both naturally and experimentally induced PrDs (14 -16), activated Caspase 3 immunoreactivity was found in only a few cells in scrapieinfected mice (73), but not in scrapie-affected sheep (70) . However, genetic manipulation of neuronal apoptotic cell death combining IPrD mouse models or BSE-infected mouse models with a Bax deletion mutation shows that Baxdependent PCD pathway may not be involved with synaptic degeneration and manifestation of neurological symptoms in those PrD mouse models (66, 74) . Recently, it has been shown that human PrP with P102L GSS syndrome mutation, but not other GSS syndrome-associated mutations, lost the anti-Bax function that prevent Bax-mediated chromatic condensation or DNA fragmentation in primary human neurons (75) . These previous reports suggested that different point mutations associated with GSS syndrome may induce the loss of neurons and the vacuole formations by activating different types of PCD pathways or by interfering with unknown signaling pathways. In this study, we used a molecular test to investigate whether Caspase 3-dependent PCD pathway is involved with the loss of locomotor abilities and early death of MoPrP P101L flies by expressing P35, a viral Caspase 3 signaling inhibitor which has previously been shown to suppress retinal cell death in rdg C and nineE (RH27) /+ flies (76) and neuronal toxicities of poly-glutamine proteins in ommatidia (77) . Concomitant expression of P35 and MoPrP P101L did not suppress the early loss in the climbing ability of flies, but significantly induced early death of flies compared with that of MoPrP P101L or P35 flies (Figs 5 and 6). These results establish that the early loss of motor controls and premature death in MoPrP P101L flies are not caused by Caspase 3-dependent PCD pathway in Drosophila. Other Caspases or autophagic cell death pathways may contribute to the onset of GSS symptoms in MoPrP P101L flies. In this study, we provided several lines of evidence that key behavioral, biochemical and pathological hallmarks of GSS syndrome observed from MoPrP P101L flies were not due to differences in the amount of expressed PrP in flies. In addition, we found that two important synaptic molecular components, Brp and DLG, were progressively reduced in MoPrP P101L flies. We also provided evidence that the activation of Caspase-3-dependent PCD is not associated with the onset and progression of behavioral defects in MoPrP P101L flies. As the studies reported here demonstrate, further studies in this Drosophila model for GSS syndrome should provide unique opportunities to obtain additional novel information about the underlying cellular and molecular mechanisms of this disorder.
MATERIALS AND METHODS
Fly genetics
Flies were raised on a standard medium at 258C. ) (78, 79) , were cloned into pUASTgermline transformation vectors. DNA sequences were confirmed again, and typical germline transformation technique procedure was followed (56) . Several independent fly lines were generated for each construct. Similar levels of expression and phenotypic properties were observed for independent isolates. Gal4 drivers. Expression of UAS-MoPrP constructs was driven by several Gal4 drivers including a Tubulin (Tub)-Gal4 driver, an Actin-5C-Gal4 driver, a C155-Gal4 driver, a Choline acetyltransferase (Cha)-Gal4 driver, a 3,4-dihydroxyphenylalanine-L-decarboxylase (Ddc)-Gal4 driver, a gliotactin-Gal4 driver, a 201Y-Gal4 driver and a C57-Gal4 driver (56) .
Generation of
Protein extraction and immunoblot analysis
Five Drosophila larvae or 10 adult heads were homogenized in RIPA buffer (20 mM HEPES, 1% Triton X-100, 1% deoxycholate, 0.1% SDS, 150 mM NaCl, pH 7.2; Sigma-Aldrich, St Louis, MO, USA) with protease inhibitors (Halt TM protease inhibitor cocktail, Thermo Fisher Scientific, Rockford, IL, USA). The protein concentration of homogenates was determined by using the BCA protein assay kit (Thermo Fisher Scientific) and prepared for SDS-PAGE. Total proteins (50 -60 mg) were separated on 8 -12% SDS-PAGE and transferred to nitrocellulose membrane (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). The blots were probed with MAb-PrP 
Animals and scrapie infection
Four-to six-week-old female C57BL/6 mice were purchased from SLC INC (Hamamatsu, Japan). They were bred and maintained in the animal facility of the Ilsong Institute of Life Science at Hallym University, Republic of Korea. The scrapie strain ME7 was kindly provided by Alan Dickinson of AFRC and MRC Institute (Edinburgh, Scotland, UK). The mice were inoculated intracerebrally with 30 ml of 1% (w/v) brain homogenate in 0.01 M phosphate-buffered saline prepared from scrapie-injected C57BL/6 mice or from control mice that had been injected with normal brain homogenate. The mice were anesthetized at 150-160 days postinoculation when clinical manifestations of disease were evident. The brains were immediately frozen and stored at 2708C until immunoblot analysis. All animal experimental procedures were examined and approved by the Animal Research Ethics Committee at the Hallym University, Republic of Korea.
Behavioral assays
Climbing ability test. Each group of flies tested for climbing abilities consisted of 10 females. Climbing assay was modified from those of Ganetzky and Wu (80) . After each group of flies was transferred into a vial, the vial was agitated by a VortexGenie bench mixer (Scientific Industries, Inc., Bohemia, NY) at the highest speed for 10 s and then left for 20 s, before counting the number of climbing flies. Flies retaining climbing abilities were considered to be those walking on the sides or tops of vials, rather than being immobilized or remaining on the bottom. Tested flies were collected from three different independent crosses. MoPrP 3F4 -expressing flies were compared with MoPrP P101L -expressing flies or genetic backgrounds of Gal4 drivers. Ten independent tests were performed for each genotype. All flies were transferred to fresh food every 2-3 days.
Survival rate analysis. Survival rates of examined flies were estimated through counting the number of dead flies every 5 days. One group, consisting of 10 age-matched adult females, was transferred to fresh food every 2 -3 days. Twosample t-tests were performed by using SigmaStat 3.1 software (Systat Software, San Jose, CA, USA).
Protease resistance assay
Ten fly heads were homogenized in RIPA buffer as described above. Equal amounts of brain homogenate were treated with different concentrations of PK (Qiagen, Hilden, Germany) at 378C for 30 min. The PK was inactivated by the addition of phenylmethylsulfonylfluoride (Sigma-Aldrich) to a final concentration of 2 mM and proteins were immediately boiled in 1× sample buffer for 5 min and subjected to immunoblot analysis utilizing MAb-PrP 3F10 and MAb-PrP 3F4 as described above.
Enzymatic deglycosylation
For deglycosylation, brain homogenates were mixed with 0.1 volume of 10× denaturing buffer (5% SDS, 0.4 M DTT) and boiled for 10 min at 958C. Samples were deglycosylated with PNGase F (New England BioLabs, Boston, MA, USA) in 50 mM sodium phosphate buffer (pH 7.5, 1% Nonidet P-40) at 378C for 18 h. Proteins were dissolved in sample buffer and used in SDS -PAGE immunoblotting.
Preparation of total RNA and semi-quantitative RT -PCR
Total RNA was extracted from eggs, larvae or fly heads using TRIzol reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). After treating with DNase I (Invitrogen), complementary DNAs (cDNAs) were synthesized from 4 mg of total RNA using cDNA synthesis kits (Promega, Madison, WI, USA) according to the manufacturer's instruction. To semi-quantify the expressed Prnp mRNA during Drosophila development, Prnp-specific primers (5 ′ -CACCATGGCGAACCTTAGCTAC-3 ′ and 5 ′ -TCATCCCACCATCAGGAAGAT-3 ′ ) and Actin-5C-specific primers (5 ′ -CATCTTCTCACGGTTGGC-3 ′ and 5 ′ -AAGGA CTCGTACGTGGGTG-3 ′ ) were used. Reactions were carried out in a GeneAmp w PCR System 9700 (Applied Biosystems, Foster City, CA, USA) using the following parameters: 15-45 PCR cycles (948C for 1 min, 558C for 1 min, 728C for 1 min). Products were run on a 1.0% agarose gel and stained with ethidium bromide. The sequences of amplified DNAs were confirmed.
Immunocytochemistry and confocal microscopy
Third star larvae were dissected in Ca 2+ -free saline (128 mM NaCl, 2 mM KCl, 4 mM MgCl 2 , 35.5 mM sucrose, 5 mM HEPES, 1 mM EGTA, pH 7.2; Sigma-Aldrich) and fixed with 4% paraformaldehyde in 0. Systems, San Jose, CA, USA). The numbers of boutons in NMJs in muscles 6 and 7 in the third abdominal segment in larvae were counted under an epifluorescence microscope. A small-sized synaptic bouton attached to the synaptic boutons in the main branches of NMJs was considered to be a satellite bouton. One-way ANOVA in SAS program (SAS Institute Inc., Cary, NC, USA) was used to perform statistical analysis.
Quantification of the intensity of Brp immunoreactivity
Larvae used for intensity analysis were processed simultaneously for MAb-Brp immunocytochemistry, and confocal images were acquired under identical settings in LSM 510 (Zeiss). Single-slice confocal images were taken from several Type 1b synaptic boutons labeled with MAb-Brp in larvae expressing MoPrP 3F4 or MoPrP P101L . The mean intensity of each MAb-Brp-specific spot in synaptic boutons or neurophils was automatically calculated by the wander tool and the histogram functions in Adobe Photoshop program. SigmaStat software was used for the two-sample t-tests.
MAb-PrP immunocytochemistry and H&E staining of adult heads
Twenty-day-old adult heads of MoPrP 3F4 or MoPrP P101L flies were fixed with 4% paraformaldehyde and processed for paraffin-embedding protocol as described previously (82) . Five microns serial paraffin sections were collected on a slide and then processed for MAb-PrP 3F4 immunocytochemistry. Donkey anti-mouse IgG-Peroxidase and 3, 3 ′ -diaminobenzidine were used for visualizing PrP localization in the adult brains (45) . To clearly visualize the vacuoles in the adult brains, the same slides were counterstained with H&E. Digital images of serial sections of adult brains were taken and processed for counting numbers of vacuoles bigger than 5 mm in diameter using Adobe Photoshop program (Adobe). The number of vacuoles in MoPrP 3F4 or MoPrP P101L was compared with two-sample t-tests using SigmaStat software.
